Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Christiaan M Roosendaal"'
Autor:
Alyssa A Toorop, Zoé L E van Kempen, Maurice Steenhuis, Jessica Nielsen, L G F Sinnige, Gert van Dijk, Christiaan M Roosendaal, Edo P J Arnoldus, Elske Hoitsma, Birgit I Lissenberg-Witte, Brigit A de Jong, Bob W van Oosten, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein
Publikováno v:
Journal of Neurology, Neurosurgery and Psychiatry, 94(6), 482-486. BMJ Publishing Group
Toorop, A A, van Kempen, Z L E, Steenhuis, M, Nielsen, J, Sinnige, L G F, van Dijk, G, Roosendaal, C M, Arnoldus, E P J, Hoitsma, E, Lissenberg-Witte, B I, de Jong, B A, Oosten, B W V, Strijbis, E M M, Uitdehaag, B M J, Rispens, T & Killestein, J 2023, ' Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, pp. 482-486 . https://doi.org/10.1136/jnnp-2022-330467
Toorop, A A, van Kempen, Z L E, Steenhuis, M, Nielsen, J, Sinnige, L G F, van Dijk, G, Roosendaal, C M, Arnoldus, E P J, Hoitsma, E, Lissenberg-Witte, B I, de Jong, B A, Oosten, B W V, Strijbis, E M M, Uitdehaag, B M J, Rispens, T & Killestein, J 2023, ' Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, pp. 482-486 . https://doi.org/10.1136/jnnp-2022-330467
BackgroundNatalizumab is effective in the treatment of multiple sclerosis (MS). In 2021, the European Medicines Agency approved the subcutaneous (SC) variant of natalizumab which can be used instead of intravenous administration. However, the course